[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 28 of about 28
1. Leibovitch I, Huilgol SC, Selva D, Richards S, Paver R: Basosquamous carcinoma: treatment with Mohs micrographic surgery. Cancer; 2005 Jul 1;104(1):170-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basosquamous carcinoma: treatment with Mohs micrographic surgery.
  • BACKGROUND: Basosquamous carcinoma (BSC) is a rare tumor defined as a basal cell carcinoma (BCC) differentiating into squamous cell carcinoma (SCC).
  • METHODS: The prospective, multicenter case series included all patients in Australia treated with MMS for BSC, who were monitored by the Skin and Cancer Foundation Australia between 1993 and 2002.
  • [MeSH-major] Carcinoma, Basosquamous / surgery. Head and Neck Neoplasms / surgery. Mohs Surgery / methods
  • [MeSH-minor] Adult. Aged. Arm. Female. Follow-Up Studies. Humans. Leg. Male. Middle Aged. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15929123.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


2. Elmets CA, Viner JL, Pentland AP, Cantrell W, Lin HY, Bailey H, Kang S, Linden KG, Heffernan M, Duvic M, Richmond E, Elewski BE, Umar A, Bell W, Gordon GB: Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst; 2010 Dec 15;102(24):1835-44
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial.
  • BACKGROUND: Preclinical studies indicate that the enzyme cyclooxygenase 2 plays an important role in ultraviolet-induced skin cancers.
  • We evaluated the efficacy and safety of celecoxib, a cyclooxygenase 2 inhibitor, as a chemopreventive agent for actinic keratoses, the premalignant precursor of nonmelanoma skin cancers, and for nonmelanoma skin cancers, including cutaneous squamous cell carcinomas (SCCs) and basal cell carcinomas (BCCs).
  • In exploratory analyses, we evaluated the number of nonmelanoma skin cancers combined and SCCs and BCCs separately per patient at 11 months after randomization using Poisson regression, after adjustment for patient characteristics and time on study.
  • However, at 11 months after randomization, there were fewer nonmelanoma skin cancers in the celecoxib arm than in the placebo arm (mean cumulative tumor number per patient 0.14 vs 0.35; rate ratio [RR] = .43, 95% confidence interval [CI] = 0.24 to 0.75; P = .003).
  • After adjusting for age, sex, Fitzpatrick skin type, history of actinic keratosis at randomization, nonmelanoma skin cancer history, and patient time on study, the number of nonmelanoma skin cancers was lower in the celecoxib arm than in the placebo arm (RR = 0.41, 95% CI = 0.23 to 0.72, P = .002) as were the numbers of BCCs (RR = 0.40, 95% CI = 0.18 to 0.93, P = .032) and SCCs (RR = 0.42, 95% CI = 0.19 to 0.93, P = .032).
  • CONCLUSIONS: Celecoxib may be effective for prevention of SCCs and BCCs in individuals who have extensive actinic damage and are at high risk for development of nonmelanoma skin cancers.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. CELECOXIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1946-52 [10874062.001]
  • [Cites] J Am Acad Dermatol. 1994 May;30(5 Pt 1):774-8 [8176018.001]
  • [Cites] J Invest Dermatol. 1994 Jun;102(6):4S-5S [8006434.001]
  • [Cites] J Invest Dermatol. 2000 Aug;115(2):273-7 [10951246.001]
  • [Cites] Int J Cancer. 2001 Jan 20;95(1):7-11 [11241303.001]
  • [Cites] Lancet. 2001 Mar 24;357(9260):926-9 [11289350.001]
  • [Cites] Arch Dermatol. 2001 Aug;137(8):1055-8 [11493098.001]
  • [Cites] Oncology (Williston Park). 2002 May;16(5 Suppl 4):37-51 [12102579.001]
  • [Cites] Photochem Photobiol. 2002 Jul;76(1):73-80 [12126310.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):891-9 [12621133.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Oct;12(10):1105-8 [14578151.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jun;13(6):920-7 [15184247.001]
  • [Cites] J Drugs Dermatol. 2004 Jul-Aug;3(4):401-7 [15303784.001]
  • [Cites] Br J Dermatol. 1994 Oct;131(4):455-64 [7947197.001]
  • [Cites] Arch Dermatol. 1995 Feb;131(2):170-5 [7857113.001]
  • [Cites] Int J Cancer. 1995 Jul 17;62(2):165-9 [7622291.001]
  • [Cites] Br J Cancer. 1996 Oct;74(8):1302-7 [8883422.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Nov;6(11):957-61 [9367070.001]
  • [Cites] Carcinogenesis. 1998 May;19(5):723-9 [9635856.001]
  • [Cites] Br J Dermatol. 1998 Dec;139(6):1033-9 [9990367.001]
  • [Cites] Mol Carcinog. 1999 Aug;25(4):231-40 [10449029.001]
  • [Cites] Lancet. 1999 Aug 28;354(9180):723-9 [10475183.001]
  • [Cites] Carcinogenesis. 1999 Oct;20(10):1939-44 [10506108.001]
  • [Cites] N Engl J Med. 2005 Mar 17;352(11):1071-80 [15713944.001]
  • [Cites] Br J Dermatol. 2005 Mar;152(3):518-23 [15787821.001]
  • [Cites] JAMA. 2005 Aug 10;294(6):681-90 [16091570.001]
  • [Cites] J Exp Med. 2005 Oct 3;202(7):931-9 [16186186.001]
  • [Cites] J Am Acad Dermatol. 2005 Dec;53(6):966-72 [16310056.001]
  • [Cites] Int J Cancer. 2006 Aug 1;119(3):682-6 [16496410.001]
  • [Cites] J Am Acad Dermatol. 2006 Sep;55(3):490-500 [16908356.001]
  • [Cites] N Engl J Med. 2006 Aug 31;355(9):873-84 [16943400.001]
  • [Cites] N Engl J Med. 2006 Aug 31;355(9):885-95 [16943401.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2546-8 [17132769.001]
  • [Cites] N Engl J Med. 2007 Jul 26;357(4):360-9 [17652651.001]
  • [Cites] Mol Carcinog. 2007 Aug;46(8):692-8 [17443745.001]
  • [Cites] Mol Carcinog. 2007 Dec;46(12):981-92 [17583568.001]
  • [Cites] Photochem Photobiol. 2008 Mar-Apr;84(2):463-76 [18248498.001]
  • [Cites] J Am Acad Dermatol. 2008 May;58(5 Suppl 2):S129-32 [18410798.001]
  • [Cites] Circulation. 2008 Apr 22;117(16):2104-13 [18378608.001]
  • [Cites] Crit Rev Oncol Hematol. 2008 Jun;66(3):208-17 [18304833.001]
  • [Cites] Mol Cancer Res. 2008 Jun;6(6):1003-16 [18567804.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Jun;1(1):21-31 [19138933.001]
  • [Cites] J Invest Dermatol. 2009 Apr;129(4):1016-25 [18843292.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2009 Apr;18(4):276-83 [19226541.001]
  • [Cites] Cancer Prev Res (Phila). 2010 Jan;3(1):25-34 [20051370.001]
  • [Cites] Cancer Prev Res (Phila). 2010 Jan;3(1):35-47 [20051371.001]
  • [Cites] Arch Dermatol. 2010 Mar;146(3):283-7 [20231499.001]
  • [Cites] Arch Dermatol. 2010 Apr;146(4):388-95 [20157019.001]
  • [Cites] Australas J Dermatol. 1983 Aug;24(2):79-82 [6661117.001]
  • [Cites] N Engl J Med. 1988 Jun 23;318(25):1633-7 [3287161.001]
  • [Cites] J Natl Cancer Inst. 1992 Mar 4;84(5):328-32 [1738183.001]
  • [Cites] JAMA. 1992 Jun 24;267(24):3305-10 [1597912.001]
  • [Cites] N Engl J Med. 1993 Oct 14;329(16):1147-51 [8377777.001]
  • [Cites] N Engl J Med. 1994 May 5;330(18):1272-5 [8145782.001]
  • [CommentIn] J Natl Cancer Inst. 2010 Dec 15;102(24):1815-7 [21115881.001]
  • [CommentIn] Arch Dermatol. 2012 May;148(5):638-40 [22782153.001]
  • (PMID = 21115882.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CN / N01-CN-85183; United States / NIAMS NIH HHS / AR / P30 AR050948; United States / NCI NIH HHS / CA / P30 CA013148
  • [Publication-type] Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Cyclooxygenase 2 Inhibitors; 0 / Pyrazoles; 0 / Sulfonamides; JCX84Q7J1L / Celecoxib
  • [Other-IDs] NLM/ PMC3001966
  •  go-up   go-down


3. Nan H, Qureshi AA, Hunter DJ, Han J: A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer. Cancer Causes Control; 2009 Mar;20(2):171-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer.
  • We evaluated the effect of MDM2 SNP309 and its interaction with the p53 Arg72Pro polymorphism on pigmentary phenotypes and skin cancer risk in a nested case-control study within the Nurses' Health Study (NHS) among 219 melanoma cases, 286 squamous cell carcinoma (SCC) cases, 300 basal cell carcinoma (BCC) cases, and 873 controls, and among controls from other studies.
  • We found that the G allele of the MDM2 SNP309 was inversely associated with the presence/absence of moles on the arm among 3,207 women pooled from controls of three nested case-control studies within the NHS.
  • No significant associations were found between the MDM2 SNP309 and any of the three types of skin cancer.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Epidemiol. 2000 Jan 1;151(1):72-7 [10625176.001]
  • [Cites] Br J Cancer. 2000 May;82(9):1605-9 [10789732.001]
  • [Cites] Photodermatol Photoimmunol Photomed. 2000 Oct;16(5):195-201 [11068857.001]
  • [Cites] Nature. 2000 Nov 16;408(6810):307-10 [11099028.001]
  • [Cites] Arch Dermatol. 2000 Dec;136(12):1550-1 [11115171.001]
  • [Cites] J Natl Cancer Inst. 2001 Jun 6;93(11):824-42 [11390532.001]
  • [Cites] J Photochem Photobiol B. 2001 Oct;63(1-3):19-27 [11684448.001]
  • [Cites] Melanoma Res. 2002 Oct;12(5):513-9 [12394194.001]
  • [Cites] Nat Genet. 2003 Mar;33(3):357-65 [12567188.001]
  • [Cites] Oncogene. 2003 May 19;22(20):3042-52 [12789279.001]
  • [Cites] Cancer Detect Prev. 2003;27(4):311-5 [12893080.001]
  • [Cites] Nat Rev Cancer. 2003 Aug;3(8):559-70 [12894244.001]
  • [Cites] Int J Cancer. 2004 Jan 10;108(2):196-9 [14639602.001]
  • [Cites] J Invest Dermatol. 2004 Oct;123(4):760-2 [15373782.001]
  • [Cites] Am J Epidemiol. 1976 Dec;104(6):609-20 [998608.001]
  • [Cites] J Am Acad Dermatol. 1983 Nov;9(5):724-33 [6358278.001]
  • [Cites] Mol Cell Biol. 1987 Feb;7(2):961-3 [3547088.001]
  • [Cites] Cell. 1992 Jun 26;69(7):1237-45 [1535557.001]
  • [Cites] Nature. 1993 Apr 29;362(6423):857-60 [8479525.001]
  • [Cites] J Clin Invest. 1994 May;93(5):2258-62 [8182158.001]
  • [Cites] BMJ. 1995 Apr 8;310(6984):912-6 [7719184.001]
  • [Cites] Oncogene. 1995 Dec 7;11(11):2445-9 [8570197.001]
  • [Cites] Nat Med. 1996 Aug;2(8):912-7 [8705862.001]
  • [Cites] Int J Epidemiol. 1996 Apr;25(2):245-51 [9119548.001]
  • [Cites] Oncogene. 1997 Mar 6;14(9):1123-8 [9070662.001]
  • [Cites] Trends Genet. 1997 Oct;13(10):410-4 [9351343.001]
  • [Cites] Oncogene. 1998 Nov 12;17(19):2543-7 [9824166.001]
  • [Cites] Mol Cell Biol. 1999 Feb;19(2):1092-100 [9891044.001]
  • [Cites] Oncogene. 1999 Feb 18;18(7):1419-34 [10050879.001]
  • [Cites] Cell. 2004 Nov 24;119(5):591-602 [15550242.001]
  • [Cites] Curr Cancer Drug Targets. 2005 Feb;5(1):3-8 [15720184.001]
  • [Cites] Int J Biochem Cell Biol. 2005 Aug;37(8):1547-53 [15896663.001]
  • [Cites] J Invest Dermatol. 2005 Dec;125(6):1252-8 [16354196.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2608-15 [16510579.001]
  • [Cites] Cancer Lett. 2006 Aug 28;240(2):195-7 [16239061.001]
  • [Cites] Clin Cancer Res. 2006 Aug 15;12(16):4867-71 [16914573.001]
  • [Cites] Int J Cancer. 2006 Oct 15;119(8):1976-84 [16721784.001]
  • [Cites] Int J Epidemiol. 2006 Dec;35(6):1514-21 [16943234.001]
  • [Cites] Gynecol Oncol. 2007 Mar;104(3):660-4 [17123590.001]
  • [Cites] Nature. 2007 Feb 22;445(7130):843-50 [17314970.001]
  • [Cites] Cell. 2007 Mar 9;128(5):853-64 [17350573.001]
  • [Cites] Cancer Causes Control. 2007 Aug;18(6):621-5 [17387621.001]
  • [Cites] Br J Dermatol. 2007 Aug;157(2):375-7 [17553029.001]
  • [Cites] Carcinogenesis. 2007 Nov;28(11):2262-7 [17827408.001]
  • [Cites] Br J Dermatol. 2008 Aug;159(2):314-21 [18510673.001]
  • (PMID = 18814047.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA122838-01A2; United States / NCI NIH HHS / CA / R01 CA122838; United States / NCI NIH HHS / CA / CA128080; United States / NCI NIH HHS / CA / R03 CA128080; United States / NCI NIH HHS / CA / CA122838
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  • [Other-IDs] NLM/ NIHMS70183; NLM/ PMC2631619
  •  go-up   go-down


Advertisement
4. Deonarine K, Panelli MC, Stashower ME, Jin P, Smith K, Slade HB, Norwood C, Wang E, Marincola FM, Stroncek DF: Gene expression profiling of cutaneous wound healing. J Transl Med; 2007;5:11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY DESIGN: This study was part of a placebo-controlled double-blind clinical trial in which basal cell carcinomas were treated topically with an immunomodifier--toll-like receptor 7 agonist: imiquimod.
  • The fourteen patients with basal cell carcinoma in the placebo arm of the trial received placebo treatment consisting solely of vehicle cream.
  • A skin punch biopsy was obtained immediately before treatment and at the end of the placebo treatment (after 2, 4 or 8 days).
  • [MeSH-major] Gene Expression Profiling. Skin / metabolism. Skin / pathology. Wound Healing / genetics

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Thromb Haemost. 2006 May;4(5):932-9 [16689737.001]
  • [Cites] Mol Cell Biol. 2000 Feb;20(3):755-9 [10629031.001]
  • [Cites] Cancer Metastasis Rev. 2006 Sep;25(3):315-22 [16967326.001]
  • [Cites] J Immunol. 2006 Nov 15;177(10):7303-11 [17082649.001]
  • [Cites] Wound Repair Regen. 2006 Mar-Apr;14(2):129-37 [16630101.001]
  • [Cites] Exp Cell Res. 2006 Mar 10;312(5):651-8 [16325811.001]
  • [Cites] J Biol Chem. 2006 Mar 3;281(9):6020-9 [16365041.001]
  • [Cites] Autoimmun Rev. 2006 Feb;5(2):129-31 [16431343.001]
  • [Cites] J Thromb Haemost. 2006 Jan;4(1):19-25 [16129024.001]
  • [Cites] Genome Biol. 2005;6(2):R15 [15693944.001]
  • [Cites] Trends Immunol. 2004 Dec;25(12):677-86 [15530839.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] N Engl J Med. 1986 Dec 25;315(26):1650-9 [3537791.001]
  • [Cites] Wound Repair Regen. 2004 Jul-Aug;12(4):461-70 [15260812.001]
  • [Cites] Keio J Med. 2004 Jun;53(2):74-7 [15247510.001]
  • [Cites] FASEB J. 2004 May;18(7):816-27 [15117886.001]
  • [Cites] Front Biosci. 2004 Jan 1;9:283-9 [14766366.001]
  • [Cites] Adv Skin Wound Care. 2004 Jan-Feb;17(1):24-35 [14752324.001]
  • [Cites] J Mol Med (Berl). 2003 Oct;81(10):600-12 [12928786.001]
  • [Cites] Nat Med. 2003 Feb;9(2):225-9 [12524533.001]
  • [Cites] Trends Immunol. 2002 Nov;23(11):549-55 [12401408.001]
  • [Cites] Wound Repair Regen. 2002 May-Jun;10(3):130-32 [12164164.001]
  • [Cites] Curr Pharm Des. 2001 Jul;7(11):1083-103 [11472255.001]
  • [Cites] Nat Cell Biol. 2000 Oct;2(10):737-44 [11025665.001]
  • [Cites] Nat Biotechnol. 2000 Apr;18(4):457-9 [10748532.001]
  • [Cites] Nat Genet. 2000 Mar;24(3):227-35 [10700174.001]
  • [Cites] Genome Biol. 2007;8(1):R8 [17222352.001]
  • (PMID = 17313672.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Biomarkers; 0 / Placebos; 99011-02-6 / imiquimod
  • [Other-IDs] NLM/ PMC1804259
  • [General-notes] NLM/ Original DateCompleted: 20070810
  •  go-up   go-down


5. Downs N, Parisi A: Measurements of the anatomical distribution of erythemal ultraviolet: a study comparing exposure distribution to the site incidence of solar keratoses, basal cell carcinoma and squamous cell carcinoma. Photochem Photobiol Sci; 2009 Aug;8(8):1195-201
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Measurements of the anatomical distribution of erythemal ultraviolet: a study comparing exposure distribution to the site incidence of solar keratoses, basal cell carcinoma and squamous cell carcinoma.
  • The UV exposures were compared with existing data detailing the anatomical distribution of basal cell carcinoma (BCC), squamous cell carcinoma (SCC) and solar keratoses (SK).
  • Surface UV exposures to unprotected skin surfaces have been presented for each of the face, neck, arm, hand and leg assessing a total of 1453 body sites (2491 measurements).
  • Detailed positions of UV exposure measured over the face, neck, arm, hand and leg were more closely related to NMSC incidence data for the face and upper limbs.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Keratosis / epidemiology. Skin / pathology. Ultraviolet Rays
  • [MeSH-minor] Arm / pathology. Arm / radiation effects. Australia / epidemiology. Dose-Response Relationship, Radiation. Environmental Exposure. Face / pathology. Face / radiation effects. Hand / pathology. Hand / radiation effects. Humans. Incidence. Leg / pathology. Leg / radiation effects. Neck / pathology. Neck / radiation effects

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19639123.001).
  • [ISSN] 1474-905X
  • [Journal-full-title] Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology
  • [ISO-abbreviation] Photochem. Photobiol. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


6. Marra DE, Torres A, Schanbacher CF, Gonzalez S: Detection of residual basal cell carcinoma by in vivo confocal microscopy. Dermatol Surg; 2005 May;31(5):538-41
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of residual basal cell carcinoma by in vivo confocal microscopy.
  • BACKGROUND: Near-infrared reflectance-mode confocal scanning laser microscopy (RCM) represents a novel imaging technique for microscopic analysis of skin lesions and may provide a noninvasive modality for the diagnosis of basal cell carcinoma (BCC).
  • CONCLUSION: We report the use of RCM in the confirmation of residual BCC in two cases and the tentative diagnosis with subsequent pathologic conformation of a third case in which a biopsy was previously inadequate.
  • Our results demonstrate that confocal microscopy may facilitate diagnosis of BCC in vivo and warrant further prospective study to quantify the sensitivity and specificity of this rapidly evolving imaging modality.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Aged. Arm. Diagnosis, Differential. Face. Forehead. Humans. Male. Microscopy, Confocal. Middle Aged. Pilot Projects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15962737.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Caekelbergh K, Nikkels AF, Leroy B, Verhaeghe E, Lamotte M, Vincent R: Photodynamic therapy using methyl aminolevulinate in the management of primary superficial basal cell carcinoma: clinical and health economic outcomes. J Drugs Dermatol; 2009 Nov;8(11):992-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy using methyl aminolevulinate in the management of primary superficial basal cell carcinoma: clinical and health economic outcomes.
  • BACKGROUND: Basal cell carcinoma (BCC) is the most common form of skin cancer worldwide.
  • METHODS: This study was a prospective, single-arm, open study conducted at eight dermatological institutions during six months after the first MAL-PDT treatment.
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Carcinoma, Basal Cell / drug therapy. Photochemotherapy / methods. Photosensitizing Agents / therapeutic use. Skin Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19894366.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


8. Soleymani AD, Scheinfeld N, Vasil K, Bechtel MA: Metastatic basal cell carcinoma presenting with unilateral upper extremity edema and lymphatic spread. J Am Acad Dermatol; 2008 Aug;59(2 Suppl 1):S1-3
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic basal cell carcinoma presenting with unilateral upper extremity edema and lymphatic spread.
  • Basal cell carcinoma (BCC), the most common human malignancy, metastasizes in 0.0028% to 0.5% of cases, usually to the lymph nodes, lungs, bones, and skin.
  • We describe metastatic basal cell carcinoma to the skin presenting with unilateral upper extremity edema.
  • [MeSH-major] Carcinoma, Basal Cell / complications. Carcinoma, Basal Cell / secondary. Edema / etiology. Skin Neoplasms / complications. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Arm. Axilla. Biopsy. Humans. Lymphatic Metastasis. Male

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Am Acad Dermatol. 2009 Apr;60(4):704 [19293022.001]
  • (PMID = 18625368.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Siller G, Rosen R, Freeman M, Welburn P, Katsamas J, Ogbourne SM: PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial. Australas J Dermatol; 2010 May;51(2):99-105
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial.
  • OBJECTIVES: To evaluate the safety of two applications of PEP005 (ingenol mebutate) gel in superficial basal cell carcinoma.
  • A total of 60 patients with histologically confirmed superficial basal cell carcinoma (lesion size, 4-15 mm) were randomized to treatment on days 1 and 2 (Arm A) or days 1 and 8 (Arm B) and, within each arm, to ingenol mebutate gel, 0.0025%, 0.01% or 0.05%, or vehicle gel.
  • The main outcome measures were the incidence and severity of adverse events and local skin responses in Arms A and B; lesion clearance at day 85 was a secondary measure.
  • One patient treated with ingenol mebutate gel, 0.05% in Arm A experienced severe flaking/scaling/dryness extending beyond the application site.
  • Six patients in Arm A had one or more severe local skin responses.
  • Efficacy appeared to be dose-related and there was a trend towards higher clinical and histological lesion clearance rates in Arm A compared with Arm B.
  • Histological clearance occurred in five of eight patients (63%) randomized to ingenol mebutate gel, 0.05% in Arm A.
  • CONCLUSIONS: Two applications of ingenol mebutate gel, 0.05%, are safe and have efficacy in patients with superficial basal cell carcinoma.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Basal Cell / drug therapy. Diterpenes / administration & dosage. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Adult. Aged. Aged, 80 and over. Dose-Response Relationship, Drug. Female. Gels. Headache / chemically induced. Humans. Male. Middle Aged. Pain / chemically induced. Remission Induction. Skin Diseases / chemically induced. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20546215.001).
  • [ISSN] 1440-0960
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / 3-ingenyl angelate; 0 / Antineoplastic Agents; 0 / Diterpenes; 0 / Gels
  •  go-up   go-down


10. Annemans L, Caekelbergh K, Roelandts R, Boonen H, Leys C, Nikkels AF, van Den Haute V, van Quickenborne L, Verhaeghe E, Leroy B: Real-life practice study of the clinical outcome and cost-effectiveness of photodynamic therapy using methyl aminolevulinate (MAL-PDT) in the management of actinic keratosis and basal cell carcinoma. Eur J Dermatol; 2008 Sep-Oct;18(5):539-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Real-life practice study of the clinical outcome and cost-effectiveness of photodynamic therapy using methyl aminolevulinate (MAL-PDT) in the management of actinic keratosis and basal cell carcinoma.
  • Clinical trials have shown that photodynamic therapy using methyl aminolevulinate (MAL-PDT) is an effective treatment for actinic keratosis (AK), and nodular and superficial basal cell carcinoma (nBCC and sBCC) unsuitable for other available therapies.
  • The objectives of this prospective, observational, one arm study were (i) to verify in a real-life practice study the results obtained in previous clinical trials with MAL-PDT in the treatment of AK, nBCC and sBCC;.
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Carcinoma, Basal Cell / drug therapy. Carcinoma, Basal Cell / economics. Keratosis, Actinic / drug therapy. Keratosis, Actinic / economics. Photochemotherapy / economics. Photosensitizing Agents / economics. Photosensitizing Agents / therapeutic use. Skin Neoplasms / drug therapy. Skin Neoplasms / economics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18693157.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


11. Betti R, Radaelli G, Mussino F, Menni S, Crosti C: Anatomic location and histopathologic subtype of basal cell carcinomas in adults younger than 40 or 90 and older: any difference? Dermatol Surg; 2009 Feb;35(2):201-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anatomic location and histopathologic subtype of basal cell carcinomas in adults younger than 40 or 90 and older: any difference?
  • BACKGROUND: Differences in age, site, and histopathologic subtype exist in basal cell carcinoma (BCC).
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Basal Cell / pathology. Head and Neck Neoplasms / epidemiology. Skin Neoplasms / epidemiology. Skin Neoplasms / pathology
  • [MeSH-minor] Abdomen. Adult. Age Distribution. Age Factors. Aged, 80 and over. Arm. Back. Female. Humans. Incidence. Leg. Male. Prevalence. Regression Analysis. Sex Distribution. Thorax

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19215256.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Aigner BA, Darsow U, Grosber M, Ring J, Plötz SG: Multiple basal cell carcinomas after long-term exposure to hydrazine: case report and review of the literature. Dermatology; 2010;221(4):300-2
Hazardous Substances Data Bank. HYDRAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple basal cell carcinomas after long-term exposure to hydrazine: case report and review of the literature.
  • It is known to be a skin sensitizer, a corrosive agent and it causes dermatitis on contact.
  • The authors report the case of a 68-year-old man with multiple basal cell carcinomas (BCCs) covering his arms and face.
  • [MeSH-major] Hydrazines / toxicity. Occupational Diseases / chemically induced. Occupational Exposure. Skin Neoplasms / chemically induced
  • [MeSH-minor] Aged. Arm. Carcinoma, Basal Cell / chemically induced. Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / surgery. Face. Hamartoma Syndrome, Multiple. Humans. Male

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. HYDRAZINE SULFATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • (PMID = 21099194.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Hydrazines; 27RFH0GB4R / hydrazine; Basal cell carcinoma, multiple
  •  go-up   go-down


13. Emanuel PO, Rudikoff D, Phelps RG: Aggressive squamous cell carcinoma in Kindler syndrome. Skinmed; 2006 Nov-Dec;5(6):305-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive squamous cell carcinoma in Kindler syndrome.
  • A 57-year-old Hispanic man with a personal and family history of bullae and photosensitivity presented with a fungating, ulcerated squamous cell carcinoma on his left hand (Figure 1).
  • There was reticulated erythema, atrophy, hyperpigmentation and hypopigmentation, and telangiectasia of sun-exposed skin of the face, neck, and hands consistent with poikiloderma (Figure 2).
  • Extensive histologic evaluation of the specimen obtained following left arm amputation and lymph node dissection showed moderate-to-poorly differentiated deeply invasive squamous cell carcinoma.
  • Two of 3 axillary lymph nodes were positive for metastatic carcinoma.
  • Electron microscopy illustrated extensive reduplication of the basement membrane, with loops, curls, and free extensions of the basal lamina in the superficial dermis; reduced numbers of hemidesmosomes and anchoring fibrils; and a basement membrane focally devoid of basal cells (Figure 4).
  • On the basis of the clinical features and the characteristic basement zone changes, a diagnosis of Kindler syndrome was made.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Epidermolysis Bullosa / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Hand / pathology. Humans. Male. Middle Aged. Syndrome


14. Giuliano CJ, Kerley-Hamilton JS, Bee T, Freemantle SJ, Manickaratnam R, Dmitrovsky E, Spinella MJ: Retinoic acid represses a cassette of candidate pluripotency chromosome 12p genes during induced loss of human embryonal carcinoma tumorigenicity. Biochim Biophys Acta; 2005 Oct 15;1731(1):48-56
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retinoic acid represses a cassette of candidate pluripotency chromosome 12p genes during induced loss of human embryonal carcinoma tumorigenicity.
  • Testicular germ cell tumors (TGCTs) are the most common carcinomas of young men aged 15-35.
  • TGCTs have near universal amplification of the short arm of chromosome 12, however positional cloning efforts have not identified causative genes on 12p involved in formation or progression of TGCTs.
  • Human embryonal carcinoma (EC) are the stem cells of TGCTs and are pluripotent.
  • EC cells terminally differentiate toward a neuronal lineage with all-trans retinoic acid (RA) treatment resulting in a concomitant G1 cell cycle arrest and loss of tumorigenicity.
  • Our efforts to define the molecular mechanisms of RA-mediated tumor cell differentiation at a critical "commitment to differentiate" window has identified a cassette of genes on 12p that are repressed with RA precisely as EC cells lose tumorigenic potential.
  • Notably, knockdown of Oct4 with siRNA results in repression of basal Nanog, EDR1, GDF3 and Stella gene expression.
  • Nanog has recently been identified to play a role in maintenance of the pluripotency of mouse embryonic stem cells and CD9, EDR1, GDF3, and Stella have each been implicated as stem cell markers.

  • Genetic Alliance. consumer health - Embryonal Carcinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16168501.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA111422; United States / NCI NIH HHS / CA / R01-CA111422; United States / NCI NIH HHS / CA / R01-CA104312; United States / NCI NIH HHS / CA / R01-CA87546; United States / NCI NIH HHS / CA / R01 CA104312
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Octamer Transcription Factor-3; 0 / POU5F1 protein, human; 0 / RNA, Small Interfering; 5688UTC01R / Tretinoin
  •  go-up   go-down


15. Kazakov DV, Mentzel T, Erlandson RA, Mukensnabl P, Michal M: Clear cell trichoblastoma: a clinicopathological and ultrastructural study of two cases. Am J Dermatopathol; 2006 Jun;28(3):197-201
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell trichoblastoma: a clinicopathological and ultrastructural study of two cases.
  • Clear cell change in basal cell carcinomas is a well-recognized phenomenon, but is obviously rare in trichoblastomas.
  • We present two cases of clear cell trichoblastoma in which clear cell change was very much prominent, and the results of an ultrastructural study intended to explore the basis of that feature.
  • Both our patients were women, aged 56 and 77 years, who presented with solitary, slowly growing nodules that measured 3 to 5 cm in largest dimension and were located on the scalp and the flexor aspect of the lower arm.
  • Common to both tumors was clear cell cytoplasm evident in the majority of the epithelial cells in one case and almost in the entire epithelial cell population in the other.
  • In most epithelial aggregations the epithelial cells with clear cytoplasm often appeared columnar and were arranged in a palisade along a recognizable basal membrane, thus indicative of outer sheath differentiation at the bulb.
  • In addition to the usual organelles, the cytoplasm contained fairly conspicuous tonofilaments and variably sized vacuoles devoid of a limiting membrane, located between the palisaded nuclei and the outer cell membrane.
  • [MeSH-major] Carcinoma, Basal Cell / ultrastructure. Head and Neck Neoplasms / ultrastructure. Neoplasms, Adnexal and Skin Appendage / ultrastructure. Skin Neoplasms / ultrastructure
  • [MeSH-minor] Aged. Basement Membrane / ultrastructure. Cell Nucleus / ultrastructure. Cytoplasm / ultrastructure. Desmosomes / ultrastructure. Epithelial Cells / ultrastructure. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16778484.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Acocella A, Sacco R, Bertolai R, Sacco N: Genetic and clinicopathologic aspects of Gorlin-Goltz syndrome (NBCCS): presentation of two case reports and literature review. Minerva Stomatol; 2009 Jan-Feb;58(1-2):43-53
Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gorlin-Goltz Syndrome (Nevoid Basal Cell Carcinoma Syndrome) is a well-known disorder with distinctive symptoms, which are studied since the 1960s.
  • Only recently it has been ascertained that it is caused by the aberration of the long arm of the chromosome 9q22.3, mapped specifically in the area of Patched gene (PTCH).
  • [MeSH-major] Basal Cell Nevus Syndrome / genetics
  • [MeSH-minor] Adult. Aged. Calcinosis / genetics. Calcinosis / radiography. Carcinoma, Basal Cell / genetics. Carcinoma, Basal Cell / surgery. Chromosomes, Human, Pair 9 / genetics. Dura Mater / pathology. Dura Mater / radiography. Facial Neoplasms / genetics. Facial Neoplasms / surgery. Female. Genes, Dominant. Hedgehog Proteins / genetics. Hedgehog Proteins / physiology. Humans. Jaw Diseases / genetics. Jaw Diseases / surgery. Loss of Heterozygosity. Male. Odontogenic Cysts / genetics. Odontogenic Cysts / surgery. Receptors, Cell Surface / genetics. Receptors, Cell Surface / physiology. Signal Transduction. Tooth Avulsion / genetics. Tooth Avulsion / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19234436.001).
  • [ISSN] 0026-4970
  • [Journal-full-title] Minerva stomatologica
  • [ISO-abbreviation] Minerva Stomatol
  • [Language] eng; ita
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Hedgehog Proteins; 0 / Receptors, Cell Surface; 0 / SHH protein, human; 0 / patched receptors
  • [Number-of-references] 38
  •  go-up   go-down


17. Mamelak AJ, Wang SQ, Goldberg LH: Linear closure for nasal defects after Mohs micrographic surgery. J Drugs Dermatol; 2009 Jan;8(1):23-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Skin cancers on the nose are very common.
  • METHODS: A retrospective analysis was conducted of 4765 patients with skin malignancies on the nose that were treated with MMS between July 1997 and January 2006.
  • In a second study arm, a limited prospective cosmetic outcome assessment of patients with nasal defects repaired by LC compared to flaps and grafts was also conducted.
  • The 2 major malignancies treated were basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Female. Humans. Male. Middle Aged. Nose Neoplasms / surgery. Prospective Studies. Retrospective Studies. Skin Transplantation. Surgical Flaps. Young Adult

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19180892.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Rogers HW, Coldiron BM: A relative value unit-based cost comparison of treatment modalities for nonmelanoma skin cancer: effect of the loss of the Mohs multiple surgery reduction exemption. J Am Acad Dermatol; 2009 Jul;61(1):96-103
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A relative value unit-based cost comparison of treatment modalities for nonmelanoma skin cancer: effect of the loss of the Mohs multiple surgery reduction exemption.
  • BACKGROUND: The incidence of skin cancer has increased dramatically, with as many as 2.8 million skin cancers treated in 2005.
  • In an era of decreasing reimbursement, insurer policy changes, and increasing pressure to deliver cost effective care, physicians should understand the total cost of different skin cancer treatment modalities in order to determine which yields the best value for patients.
  • OBJECTIVE: To estimate the costs of treating nonmelanoma skin cancers by multiple modalities based on their assigned relative value unit (RVU) values.
  • METHODS: The cost analysis was performed for the treatment of two skin cancer examples, a basal cell carcinoma (BCC) on the central cheek and a squamous cell carcinoma (SCC) on the forearm of varying sizes.
  • The estimated costs of treatment of each of the skin cancers was calculated for treatment with electrodessication and curettage (EDC), imiquimod immunotherapy, Mohs micrographic surgery, traditional surgical excision with permanent section margin evaluation in an office setting (with immediate repair or with repair delayed until clear margins are confirmed), surgical excision with frozen section margin control in both an ambulatory surgery center and hospital-based setting, and radiation therapy.
  • RESULTS: Our estimation of costs for each of the treatment modalities reveals that EDC is the least expensive option, with average costs of $471 (BCC cheek) and $392 (SCC arm).
  • Imiquimod treatment and office-based excision with immediate repair of the surgical defect have similar total average costs of $959 (BCC cheek) and $931 (SCC arm) and $1006 (BCC cheek) and $907 (SCC arm), respectively.
  • The average cost of Mohs micrographic surgery is $1263 (BCC cheek) and $1131 (SCC arm).
  • Excision with frozen section margin control in an ambulatory surgery center results in costs of $2334 (BCC cheek) and $2200 (SCC arm).
  • The cost of radiation therapy treatment is $2591 to $3460 for the BCC of the cheek and $2559 to $3431 for the SCC of the arm, depending on the fractional dose used.
  • CONCLUSION: Tumor destruction by EDC or imiquimod and office-based procedures, such as traditional surgical excision or Mohs surgery, are the lowest cost options for treatment of nonmelanoma skin cancer.
  • [MeSH-major] Mohs Surgery / economics. Skin Neoplasms / economics. Skin Neoplasms / surgery
  • [MeSH-minor] Ambulatory Surgical Procedures / economics. Aminoquinolines / economics. Aminoquinolines / therapeutic use. Carcinoma, Basal Cell / economics. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / economics. Carcinoma, Squamous Cell / surgery. Cheek / surgery. Cost-Benefit Analysis. Curettage / economics. Frozen Sections / economics. Humans. Reconstructive Surgical Procedures / economics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Am Acad Dermatol. 2010 Feb;62(2):347-8 [20115957.001]
  • (PMID = 19539843.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 99011-02-6 / imiquimod
  •  go-up   go-down


19. Madsen AR, Gundgaard MG, Hoff CM, Maare C, Holmboe P, Knap M, Thomsen LL, Buchwald C, Hansen HS, Bretlau P, Grau C: Cancer of the external auditory canal and middle ear in Denmark from 1992 to 2001. Head Neck; 2008 Oct;30(10):1332-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer of the external auditory canal and middle ear in Denmark from 1992 to 2001.
  • BACKGROUND: In the context of the Danish Head and Neck Cancer Group, nationwide material from 1992-2001 was analyzed to study the extent and nature of the disease, evaluate treatment, compare staging systems, and examine prognosis and survival.
  • METHODS: Review of 68 consecutive cases: 47 squamous cell carcinoma, 10 basal cell carcinoma, and 11 other histologies.
  • [MeSH-major] Carcinoma / pathology. Carcinoma / therapy. Ear Canal. Ear Neoplasms / pathology. Ear Neoplasms / therapy. Ear, Middle
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Denmark. Female. Humans. Kaplan-Meier Estimate. Male. Medical Records. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Neoplasm Staging. Prognosis. Retrospective Studies. Temporal Bone / pathology. Temporal Bone / surgery. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 Wiley Periodicals, Inc. Head Neck 2008.
  • (PMID = 18704969.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Manohar A, Nizlan MN: Chronic nonhealing ulcer of the right thumb with multiple subcutaneous nodules. Orthopedics; 2008 Jul;31(7):710
Hazardous Substances Data Bank. Itraconazole .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three months after the onset of the initial lesion, multiple painless erythematous nodules had developed on his right arm, and one on the right thigh.
  • A diagnosis of sporotrichosis of the right upper limb was made and the patient was started on antifungal treatment immediately (T.
  • [MeSH-major] Itraconazole / therapeutic use. Skin Ulcer / diagnosis. Skin Ulcer / drug therapy. Sporotrichosis / diagnosis. Sporotrichosis / drug therapy. Thumb / pathology
  • [MeSH-minor] Antifungal Agents / therapeutic use. Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / surgery. Chronic Disease. Diagnosis, Differential. Humans. Male. Middle Aged. Skin Neoplasms / diagnosis. Skin Neoplasms / surgery. Treatment Failure. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19292371.001).
  • [ISSN] 0147-7447
  • [Journal-full-title] Orthopedics
  • [ISO-abbreviation] Orthopedics
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 304NUG5GF4 / Itraconazole
  •  go-up   go-down


21. Choo R, Woo T, Assaad D, Antonyshyn O, Barnes EA, McKenzie D, Fialkov J, Breen D, Mamedov A: What is the microscopic tumor extent beyond clinically delineated gross tumor boundary in nonmelanoma skin cancers? Int J Radiat Oncol Biol Phys; 2005 Jul 15;62(4):1096-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] What is the microscopic tumor extent beyond clinically delineated gross tumor boundary in nonmelanoma skin cancers?
  • PURPOSE: To quantify the microscopic tumor extension beyond clinically delineated gross tumor boundary in nonmelanoma skin cancers.
  • METHODS AND MATERIALS: A prospective, single arm, study.
  • CONCLUSIONS: The distance of microscopic tumor extension beyond a gross nonmelanoma skin cancer was variable, with a mean of 5.2 mm.
  • Such information is critical for the proper radiation planning of skin cancer therapy.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15990014.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Castillo-Martin M, Domingo-Domenech J, Karni-Schmidt O, Matos T, Cordon-Cardo C: Molecular pathways of urothelial development and bladder tumorigenesis. Urol Oncol; 2010 Jul-Aug;28(4):401-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bladder cancer is the fifth most common human malignancy and the second most frequently diagnosed genitourinary tumor after prostate cancer.
  • Several studies have revealed that distinct genotypic and phenotypic patterns are associated with early vs. late stages of bladder cancer.
  • (1) superficial papillary bladder tumors, which are characterized by gain-of-function mutations affecting oncogenes such as H-RAS, FGFR3, and PI3K, and deletions of the long arm of chromosome 9 (9q);.
  • (2) Carcinoma in situ, a "flat" high grade lesion considered to be a precursor of invasive cancer, is characterized by loss-of-function mutations affecting tumor suppressor genes, such as p53, RB, and PTEN.
  • Normal urothelium is a pseudo-stratified epithelium that coats the bladder, composed of 3 cell types: basal, intermediate, and superficial ("umbrella") cells.
  • Briefly, it is our working hypothesis that 2 distinct progenitor cells are responsible for basal/intermediate cells and "umbrella" cells, respectively.
  • Basal and intermediate cells are characterized by a p63 positive phenotype, as well as expression of high molecular weight cytokeratins (CKs), such as CK5, CK10, and CK14.
  • Neither urothelial stem cells nor bladder cancer stem cells have been identified to date.
  • [MeSH-minor] Animals. Cell Transformation, Neoplastic. Genes, Tumor Suppressor / physiology. Humans. Neoplasm Invasiveness. Oncogenes / physiology. Urothelium / cytology. Urothelium / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010. Published by Elsevier Inc.
  • (PMID = 20610278.001).
  • [ISSN] 1873-2496
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


23. Conroy H, Marshall NA, Mills KH: TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours. Oncogene; 2008 Jan 7;27(2):168-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Toll-like receptor (TLR) agonists are potent activators of innate immune responses, activating dendritic cell (DC) maturation and inflammatory cytokine secretion by innate immune cells and as a consequence they promote adaptive immune response when coadministered with foreign antigens.
  • Therefore, they have been exploited as adjuvants for tumour vaccines or as immunotherapeutics against cancer.
  • Clinical evaluation of TLR agonists has resulted in a licensed immunotherapeutic for basal cell carcinoma, but there have also been disappointing results from clinical trials, with one pharmaceutical company recently halting its clinical programme.
  • A major obstacle to the development of any active immunotherapeutic approach to cancer is the immunosuppressive environment of the growing tumour, including the induction of tolerogenic DCs and regulatory T (Treg) cells, which suppress the development of protective effector T-cell responses.
  • Alternatively, manipulating the TLR-activated innate immune responses to selectively blocking immunosuppressive arm, as well as that induced by the tumour, may hold the key to enhancing their efficacy as tumour immunotherapeutics and as adjuvants for cancer vaccines.
  • [MeSH-minor] Animals. Cancer Vaccines / therapeutic use. Chemotherapy, Adjuvant. Dendritic Cells / immunology. Humans. Immunotherapy, Adoptive. Lymphocyte Activation / drug effects. Models, Biological

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18176598.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cancer Vaccines; 0 / Ligands; 0 / Toll-Like Receptors
  • [Number-of-references] 133
  •  go-up   go-down


24. Abedalthagafi M, Rushing EJ, Auerbach A, Desouki MM, Marwaha J, Wang Z, Fanburg-Smith JC: Sporadic cutaneous angiosarcomas generally lack hypoxia-inducible factor 1alpha: a histologic and immunohistochemical study of 45 cases. Ann Diagn Pathol; 2010 Feb;14(1):15-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cutaneous angiosarcoma (AS) is a rare malignant neoplasm of dermis composed of infiltrating cells of endothelial phenotype with overall poor prognosis.
  • Tumors presented most commonly in the skin of the scalp followed by the left lower leg, face, nose, lower arm, neck, thigh, eyelid, ear, and temple.
  • Associated basal cell carcinoma was noted in 1 patient; no others had other neoplasms or unrelated surgeries.
  • Requirement for diagnosis includes extravascular proliferation of atypical endothelial cells with mitotic activity in vasoformative, solid, and papillary patterns.
  • [MeSH-major] Dermis / metabolism. Hemangiosarcoma / metabolism. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Neovascularization, Pathologic / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anoxia / metabolism. Anoxia / pathology. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Inc.
  • (PMID = 20123452.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit
  •  go-up   go-down


25. Candelaria M, Cetina L, Dueñas-González A: Anemia in cervical cancer patients: implications for iron supplementation therapy. Med Oncol; 2005;22(2):161-8
Hazardous Substances Data Bank. IRON, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anemia in cervical cancer patients: implications for iron supplementation therapy.
  • Iron deficiency and tumor bleeding are common causes of anemia in cervical cancer.
  • Untreated cervical cancer patients with a hemoglobin <12 g/dL were randomized to intramuscular iron or to transfusion.
  • Mean basal hemoglobin levels were 9.9 and 9.5 g/dL respectively.
  • At wk 1 of treatment and thereafter, levels were higher in the iron arm, in whom the values were close or higher than 12 g/dL (p=0.03).
  • The median number of units transfused were 0 in the iron group and 2 in the transfusion (p=0.02) arm.
  • Parenteral iron seems to be effective to increase hemoglobin in cervical cancer patients.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Adult. Aged. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Female. Hemoglobins / drug effects. Humans. Infusions, Intravenous. Middle Aged. Pilot Projects. Treatment Outcome


26. Dunning K, Gopaldas RR, Rohatgi C: The role of amputation in treating large Basal cell carcinomas of the extremity. Plast Reconstr Surg; 2007 May;119(6):1974-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of amputation in treating large Basal cell carcinomas of the extremity.
  • [MeSH-major] Amputation / methods. Arm / surgery. Carcinoma, Basal Cell / surgery. Lymph Nodes / pathology. Neoplasm Invasiveness / pathology. Skin Neoplasms / surgery
  • [MeSH-minor] Aged, 80 and over. Axilla. Biopsy, Needle. Humans. Immunohistochemistry. Neoplasm Staging. Prognosis. Quality of Life. Risk Assessment. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17440409.001).
  • [ISSN] 1529-4242
  • [Journal-full-title] Plastic and reconstructive surgery
  • [ISO-abbreviation] Plast. Reconstr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


27. Fang W, Chen D, Shang JF, Wang F, Xiao L: [Microcystic adnexal carcinoma: report of two cases]. Zhonghua Bing Li Xue Za Zhi; 2009 Jan;38(1):59-60
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Microcystic adnexal carcinoma: report of two cases].
  • [MeSH-major] Carcinoma, Skin Appendage / pathology. Head and Neck Neoplasms / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Arm. Carcinoembryonic Antigen / metabolism. Carcinoma, Basal Cell / pathology. Diagnosis, Differential. Humans. Male. Middle Aged. Mucin-1 / metabolism

  • Genetic Alliance. consumer health - Microcystic adnexal carcinoma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19489229.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Mucin-1
  •  go-up   go-down


28. Bugatti L, Filosa G: The birhombic transposition flap to repair cutaneous lesions. J Eur Acad Dermatol Venereol; 2005 Jul;19(4):503-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Skin Neoplasms / surgery. Surgical Flaps
  • [MeSH-minor] Aged. Aged, 80 and over. Arm. Face. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15987305.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] Netherlands
  •  go-up   go-down






Advertisement